Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
0.3500
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
October 23, 2023
Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement.
Via
Benzinga
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
October 22, 2023
Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts
Via
Benzinga
Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business
October 20, 2023
Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc.
Via
Benzinga
Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement
October 18, 2023
Short-acting psychedelics biotech Small Pharma Inc.
Via
Benzinga
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
October 16, 2023
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution
Via
Benzinga
Exposures
Product Safety
What 11 Analyst Ratings Have To Say About Cybin
September 01, 2023
Via
Benzinga
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates
October 13, 2023
Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc.
Via
Benzinga
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
October 06, 2023
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
Via
Benzinga
Cybin Completes Dosing In Phase 2 Study Of CYB003 For Major Depressive Disorder Treatment
October 03, 2023
Cybin Inc. (NYSE: CYBN), a clinical-stage biotech company developing novel psychedelic-based mental health treatments, has completed dosing of the final participant cohort in the
Via
Benzinga
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
October 03, 2023
NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management...
Via
Benzinga
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
October 02, 2023
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...
Via
Benzinga
Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression
September 26, 2023
Clinical-stage psychedelics biotech Cybin Inc.
Via
Benzinga
Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results
September 26, 2023
New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.
Via
Benzinga
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
September 26, 2023
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression
September 21, 2023
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive...
Via
Benzinga
Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
September 20, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday.
Via
Benzinga
Why Elutia Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
September 19, 2023
Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares rose 73.5% to $0.1313 in pre-market trading after falling 15% on Monday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
September 19, 2023
Pre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest traders this morning!
Via
InvestorPlace
Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update
September 18, 2023
Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).
Via
Benzinga
The 3 Most Undervalued Under-$1 Stocks to Buy in September 2023
September 14, 2023
Cheap valuations and prospects for future growth should get individual investors excited for these under-$1 stocks to buy.
Via
InvestorPlace
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
September 12, 2023
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
Via
Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
September 11, 2023
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT
September 05, 2023
The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
September 05, 2023
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Via
Benzinga
Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
August 31, 2023
Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka...
Via
Benzinga
Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M
August 29, 2023
Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9...
Via
Benzinga
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
August 28, 2023
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Via
Benzinga
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
August 28, 2023
Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o
Via
Benzinga
Funding The Future Of Psychedelics: Cybin Launches Renewed ATM Equity Program Up To $35M
August 24, 2023
Psychedelics biotech Cybin Inc. (NYSE: CYBN) announced it has renewed its previously established at-the-market (ATM) equity program allowing the company to gradually issue and sell up to $35 million...
Via
Benzinga
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
August 21, 2023
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds
Via
Benzinga
Topics
Cannabis
Economy
Exposures
Cannabis
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.